Skip to content
OpenCapital
Get started

Edwards Lifesciences EW Transcatheter Mitral and Tricuspid Therapies — Net Sales

Other product segments

Transcatheter Aortic Valve Replacement
$1.2B+14.4%
Surgical
$276.2M—

Similar metrics at other companies

Boston Scientific logo
BSXInterventional Cardiology & Vascular Therapies — Net Sales
$1.24B+10.7%
Boston Scientific logo
BSXInterventional Cardiology & Vascular Therapies — Net Sales
$1.16B+10.5%
Boston Scientific logo
BSXCardiac Rhythm Management — Net Sales
$578M0.0%
AngioDynamics logo
ANGOMed Tech — Net Sales
$37.28M+19.0%
ITG
ITGRCardiac Rhythm Management & Neuromodulation — Total sales
$168.26M+4.9%
Baxter International logo
BAXMedical Products & Therapies — Net Sales
$1.29B+1.8%

Other financials

Income statement

See full
Revenue$1.6B+16.7%
Gross profit$1.3B+15.7%
Operating income$477.6M+21.0%
Net income$380.7M+6.3%
EPS (diluted)$0.66+8.2%

Balance sheet

See full
Cash & equivalents$2.4B-22.3%
Total debt$702.9M+0.5%
Total equity$10.3B+2.0%
Total assets$13.3B+2.3%

Cash flow

See full
Operating cash flow$43.8M-84.4%
CapEx$64.9M+15.9%
Free cash flow-$21.1M-109%

Valuation

See full
Market cap$51.66B+19.3%
Enterprise value$49.92B+22.2%
P/E47.1×+36.8×
P/S8.2×+0.4×

Profitability

See full
Gross margin77.9%-1.6pp
Operating margin21.4%-4.4pp
Net margin17.4%-58.3pp
FCF margin17.3%—

Returns & leverage

See full
Return on equity10.7%-37.8pp
Debt / equity0.1×0.0×
Current ratio4.4×0.0×

Where this comes from

Reported directly by Edwards Lifesciences in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Edwards Lifesciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edwards Lifesciences's transcatheter mitral and tricuspid therapies — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Edwards Lifesciences's transcatheter mitral and tricuspid therapies — net sales?
Edwards Lifesciences (EW) reported transcatheter mitral and tricuspid therapies — net sales of $175.1M in Q1 2026.
How has Edwards Lifesciences's transcatheter mitral and tricuspid therapies — net sales changed year-over-year?
Edwards Lifesciences's transcatheter mitral and tricuspid therapies — net sales increased by 52.0% year-over-year, from $115.2M to $175.1M.
What is the long-term trend for Edwards Lifesciences's transcatheter mitral and tricuspid therapies — net sales?
Over 4 years (2021 to 2025), Edwards Lifesciences's transcatheter mitral and tricuspid therapies — net sales has grown at a 59.1% compound annual growth rate (CAGR), from $86M to $550.6M.
What does transcatheter mitral and tricuspid therapies — net sales mean?
This metric represents the total revenue generated from the sale of medical devices designed for minimally invasive treatment of mitral and tricuspid heart valve diseases. It reflects the company's market penetration and adoption rates of advanced transcatheter technologies as alternatives to traditional open-heart surgery. Growth in this segment is a primary indicator of the firm's innovation pipeline success and its ability to capture share in the structural heart disease market.